natriumalginaat/natriumbicarbonaat unither pharmaceuticals 500mg/267mg, suspensie voor oraal gebruik in sachet
unither pharmaceuticals 151 rue andré durouchez, espace industriel nord 80084 amiens cedex 2 (frankrijk) - natriumalginaat (e 401) ; natriumwaterstofcarbonaat (e 500 (ii)) - suspensie voor oraal gebruik - calciumcarbonaat (e 170) ; carbomeer 974p ; natriumhydroxide (e 524) ; natriummethylparahydroxybenzoaat (e 219) ; natriumpropylparahydroxybenzoaat (e 217) ; pepermuntolie ; saccharoide natrium x-water (e 954) ; water, gezuiverd, - alginic acid
robinul 0.2 mg/ml inj. opl. i.v./i.m. amp.
eumedica pharmaceuticals gmbh - glycopyrroniumbromide 0,2 mg - oplossing voor injectie - 0,20 mg/ml - glycopyrroniumbromide 0.2 mg/ml - glycopyrronium bromide
symkevi
vertex pharmaceuticals (ireland) limited - tezacaftor, ivacaftor - taaislijmziekte - andere producten van het ademhalingssysteem - symkevi is indicated in a combination regimen with ivacaftor tablets for the treatment of patients with cystic fibrosis (cf) aged 6 years and older who are homozygous for the f508del mutation or who are heterozygous for the f508del mutation and have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (cftr) gene: p67l, r117c, l206w, r352q, a455e, d579g, 711+3a→g, s945l, s977f, r1070w, d1152h, 2789+5g→a, 3272 26a→g, and 3849+10kbc→t.
sitagliptin sandoz gmbh 25 mg filmomh. tabl.
sandoz gmbh - sitagliptinehydrochloridemonohydraat 28,34 mg - eq. sitagliptine 25 mg - filmomhulde tablet - 25 mg - sitagliptinehydrochloridemonohydraat 28.34 mg - sitagliptin
sitagliptin sandoz gmbh 50 mg filmomh. tabl.
sandoz gmbh - sitagliptinehydrochloridemonohydraat 56,69 mg - eq. sitagliptine 50 mg - filmomhulde tablet - 50 mg - sitagliptinehydrochloridemonohydraat 56.69 mg - sitagliptin
sitagliptin sandoz gmbh 100 mg filmomh. tabl.
sandoz gmbh - sitagliptinehydrochloridemonohydraat 113,38 mg - eq. sitagliptine 100 mg - filmomhulde tablet - 100 mg - sitagliptinehydrochloridemonohydraat 113.38 mg - sitagliptin
sitagliptin sandoz gmbh 100 mg filmomh. tabl.
sandoz gmbh - sitagliptinehydrochloridemonohydraat 113,38 mg - eq. sitagliptine 100 mg - filmomhulde tablet - sitagliptin
sitagliptin sandoz gmbh 25 mg filmomh. tabl.
sandoz gmbh - sitagliptinehydrochloridemonohydraat 28,34 mg - eq. sitagliptine 25 mg - filmomhulde tablet - sitagliptin
sitagliptin sandoz gmbh 50 mg filmomh. tabl.
sandoz gmbh - sitagliptinehydrochloridemonohydraat 56,69 mg - eq. sitagliptine 50 mg - filmomhulde tablet - sitagliptin
vanflyta
daiichi sankyo europe gmbh - quizartinib dihydrochloride - leukemie, myeloïde - antineoplastic agents, protein kinase inhibitors - vanflyta is indicated in combination with standard cytarabine and anthracycline induction and standard cytarabine consolidation chemotherapy, followed by vanflyta single-agent maintenance therapy for adult patients with newly diagnosed acute myeloid leukaemia (aml) that is flt3-itd positive.